Roche Holding AG RHHVF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RHHVF is a good fit for your portfolio.
News
-
Roche Raises Earnings Guidance After Results Beat Market Expectations — Update
-
Roche Raises Guidance After Sales, Earnings Beat Market Expectations
-
Eli Lilly's stock plunges as investors eye obesity-drug competition
-
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
-
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial — 3rd Update
-
Roche shares jump on drugmaker's early-stage data on weight-loss drug
-
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial — 2nd Update
-
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial — Update
Trading Information
- Previous Close Price
- $316.67
- Day Range
- $319.72–325.13
- 52-Week Range
- $233.12–325.13
- Bid/Ask
- $290.76 / $339.99
- Market Cap
- $255.27 Bil
- Volume/Avg
- 76,898 / 6,406
Key Statistics
- Price/Earnings (Normalized)
- 14.23
- Price/Sales
- 3.77
- Dividend Yield (Trailing)
- 3.39%
- Dividend Yield (Forward)
- 3.39%
- Total Yield
- 3.39%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 103,605
- Website
- https://www.roche.com
Competitors
Valuation
Metric
|
RHHVF
|
ABBV
|
MRK
|
---|---|---|---|
Price/Earnings (Normalized) | 14.23 | 16.89 | 57.72 |
Price/Book Value | 7.92 | 40.83 | 7.86 |
Price/Sales | 3.77 | 5.97 | 5.19 |
Price/Cash Flow | 13.75 | 17.45 | 18.27 |
Price/Earnings
RHHVF
ABBV
MRK
Financial Strength
Metric
|
RHHVF
|
ABBV
|
MRK
|
---|---|---|---|
Quick Ratio | 0.80 | 0.72 | 0.68 |
Current Ratio | 1.26 | 0.94 | 1.25 |
Interest Coverage | 11.62 | 3.95 | 3.97 |
Quick Ratio
RHHVF
ABBV
MRK
Profitability
Metric
|
RHHVF
|
ABBV
|
MRK
|
---|---|---|---|
Return on Assets (Normalized) | 16.64% | 14.14% | 5.22% |
Return on Equity (Normalized) | 53.11% | 172.29% | 13.56% |
Return on Invested Capital (Normalized) | 25.43% | 27.87% | 8.29% |
Return on Assets
RHHVF
ABBV
MRK
Drug Manufacturers - General Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Eli Lilly and Co
LLY
| Ftgqgmbtnt | Tljs | $724.5 Bil | |||
Johnson & Johnson
JNJ
| Wrrhcrrdh | Zvb | $386.7 Bil | |||
AbbVie Inc
ABBV
| Qhhbdygs | Nclhq | $327.0 Bil | |||
Merck & Co Inc
MRK
| Hfqxzgjyq | Zvlnq | $317.3 Bil | |||
Roche Holding AG ADR
RHHBY
| Cjyfwtwy | Vqxy | $261.9 Bil | |||
AstraZeneca PLC ADR
AZN
| Kycdvhygv | Wphxw | $242.7 Bil | |||
Novartis AG ADR
NVS
| Zspbbjfk | Mgcl | $224.0 Bil | |||
Amgen Inc
AMGN
| Wxkflbylck | Kbdk | $179.6 Bil | |||
Pfizer Inc
PFE
| Rwmbhwlf | Nqvz | $174.4 Bil | |||
Sanofi SA ADR
SNY
| Fltsdrgy | Hcxm | $131.7 Bil |